The company is focused on creating novel drugs based on G protein-coupled receptors, which are involved in a wide range of physiological processes and are targets for many therapeutic drugs. Axovan AG's biopharmaceutical research aims to discover new drugs that can be brought to market quickly, providing patients with faster access to potentially life-saving treatments. By leveraging its expertise in G protein-coupled receptors, Axovan AG is poised to make significant contributions to the field of drug development and improve patient outcomes.